Group 1 :PM8002

2 trials

Sponsors

Jilin Provice Cancer Hospital, Fudan University Shanghai Cancer Center

Conditions

malignant mesotheliomatriple-negative breast cancer

Phase 2

A phase II study of PM8002 injection in combination with standard chemotherapy as first line therapy in unresectable malignant mesothelioma

Active, not recruitingChiCTR2200060395

Jilin Provice Cancer Hospitalmalignant mesothelioma

Start: 2022-05-20Updated: 2024-05-13

A phase Ib/II study of PM8002 injection plus nab-paclitaxel as first line therapy for unresectable, locally advanced or metastatic triple-negative breast cancer

Active, not recruitingChiCTR2200060400

Fudan University Shanghai Cancer Centertriple-negative breast cancer

Start: 2022-05-20Updated: 2024-05-13

Related Papers

A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer.

Journal of Clinical Oncology2023-06-01